Windlas Biotech share news, announcements and annual reports
NSE: WINDLASBSE: 543329Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹923.40.
30 Oct: open ₹920.80, high ₹921.70, low ₹865.50
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,808 Cr1,237th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.22
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 3.11
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.72%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,27757.3% delivered
Windlas Biotech share news and announcements
325 announcements, routine notices left out, newest first. Page 4 of 7.
May 2024
20 May · Board meeting
20 May · Results
13 May · Analysts
4 May · Updates
1 May · Analysts
1 May · Analysts
Apr 2024
29 Apr · Analysts
24 Apr · Analysts
14 Apr · Analysts
Feb 2024
20 Feb · Analysts
20 Feb · Analysts
14 Feb · Analysts
14 Feb · Analysts
8 Feb · Board meeting
8 Feb · Results
Jan 2024
30 Jan · Analysts
30 Jan · Board meeting
12 Jan · Analysts
5 Jan · Analysts
4 Jan · Analysts
Dec 2023
12 Dec · Analysts
Nov 2023
23 Nov · Analysts
8 Nov · Results
8 Nov · Board meeting
3 Nov · Analysts
Oct 2023
30 Oct · Board meeting
20 Oct · Analysts
16 Oct · Analysts
11 Oct · Analysts
Sep 2023
22 Sep · Analysts
12 Sep · Meeting
4 Sep · Analysts
Aug 2023
28 Aug · Analysts
18 Aug · Updates
16 Aug · Corporate action
8 Aug · Results
2 Aug · Analysts
Jul 2023
31 Jul · Board meeting
7 Jul · Analysts
5 Jul · Analysts
5 Jul · Analysts
Jun 2023
22 Jun · Analysts